Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

被引：0
|
作者：
Lewiecki, E. Michael [1 ]
Dinavahi, Rajani V. [2 ]
Lazaretti-Castro, Marise [3 ]
Ebeling, Peter R. [4 ]
Adachi, J. [5 ]
Miyauchi, Akimitsu [6 ]
Gielen, Evelien [7 ]
Milmont, Cassandra E. [2 ]
Libanati, Cesar [8 ]
Grauer, Andreas [2 ]
机构：
[1] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Univ Fed Sao Paulo, Sao Paulo, Brazil
[4] Monash Univ, Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON, Canada
[6] Miyauchi Med Ctr, Osaka, Japan
[7] Univ Hosp Leuven, Leuven, Belgium
[8] UCB Pharma, Brussels, Belgium
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results fromthe European Forsteo Observational Study
    Aloumanis, K.
    Karras, D.
    Drossinos, V.
    Korelis, E.
    Polydorakis, A.
    JOURNAL OF OSTEOPOROSIS, 2011, 2011
  • [42] Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
    McClung, Michael R.
    Langdahl, Bente
    Papapoulos, Socrates
    Saag, Kenneth G.
    Bone, Henry
    Kiel, Douglas P.
    Lippuner, Kurt
    Nakamura, Toshitaka
    Reid, Ian
    Heyden, Norman
    DaSilva, Carolyn
    Scott, Boyd B.
    Massaad, Rachid
    Kaufman, Keith D.
    Stoch, Aubrey
    Santora, Arthur
    Gurner, Deborah
    Lombardi, Antonio
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [43] Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-term Odanacatib Fracture Trial (LOFT)
    McClung, Michael R.
    Langdahl, Bente
    Papapoulos, Socrates
    Saag, Kenneth G.
    Bone, Henry
    Kiel, Douglas P.
    Lippuner, Kurt
    Nakamura, Toshitaka
    Reid, Ian
    Heyden, Norman
    DaSilva, Carolyn
    Scott, Boyd B.
    Massaad, Rachid
    Kaufman, Keith D.
    Stoch, S. Aubrey
    Santora, Arthur
    Gurner, Deborah
    Lombardi, Antonio
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016, 23 (12): : 1369 - 1369
  • [44] Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated for up to 10 Years with Denosumab: Results from a Phase 3 Open-Label Extension Study
    Watts, Nelson B.
    Grbic, John T.
    Binkley, Neil
    Butler, Peter W.
    Yin, Xiang
    Tierney, Antoniette
    Wagman, Rachel B.
    McClung, Michael
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [45] 6 months changes in biochemical markers predict 3-year response in vertebral fracture rate in postmenopausal, osteoporotic women: Results from the MORE study.
    Bjarnason, NH
    Christiansen, C
    Sarkar, S
    Mitlak, B
    Knickerbocker, R
    Delmas, P
    Cummings, S
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S157 - S157
  • [46] Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis:: Results of a double-blind, placebo-controlled 3-year study
    McCloskey, E
    Selby, P
    Davies, M
    Robinson, J
    Francis, RM
    Adams, J
    Kayan, K
    Beneton, M
    Jalava, TI
    Pylkkänen, L
    Kenraali, J
    Aropuu, S
    Kanis, JA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (05) : 728 - 736
  • [47] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial (vol 282, pg 637, 1999)
    Ettinger, B
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (22): : 2124 - 2124
  • [48] Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension
    Recker, Robert
    Dempster, David
    Langdahl, Bente
    Giezek, Hilde
    Clark, Seth
    Ellis, Graham
    de Villiers, Tobias
    Valter, Ivo
    Zerbini, Cristiano A. F.
    Cohn, Dosinda
    Santora, Arthur
    Duong, Le T.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 (07) : 1289 - 1299
  • [49] Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study (vol 22, pg 462, 2004)
    Kushida, K
    Shiraki, M
    Nakamura, T
    Kishimoto, H
    Morii, H
    Yamamoto, K
    Kaneda, K
    Fukunaga, M
    Inoue, T
    Nakashima, M
    Orimo, H
    JOURNAL OF BONE AND MINERAL METABOLISM, 2005, 23 (01) : 95 - 95
  • [50] BAZEDOXIFENE 20MG RETAINS TRABECULAR AND CORTICAL BONE MINERAL MASS, CORTICAL GEOMETRY AND DERIVED STRENGTH AFTER 12 MONTHS OF TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: A SINGLE-ARM, PHASE IV, TIBIA PQCT STUDY
    Stathopoulos, K. D.
    Kosmidis, C.
    Mavrogenis, A.
    Atsali, E.
    Bournazos, I.
    Papagelopoulos, P. J.
    Skarantavos, G.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S521 - S522
12345